A Phase 2 interventional study of N-acetylcysteine in Hepatic and Post Hepatic Jaundice, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Tanta University · Phase 2, Interventional, and Treatment
Investigating the efficacy, safety, and molecular mechanism of N-acetylcysteine supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice.
84 studies on the registry are indexed under Jaundice; 13 are open to participants now.
This study's enrollment of 44 is below the median of 79 across 47 interventional studies indexed under Jaundice.
Browse Jaundice studies →Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
22 patients who will receive supportive treatment for jaundice only, for 3 months.
22 patients who will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
Drug: N-acetylcysteine
Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
The change from baseline in (Total and Direct bilirubin)
measurement of (Total and Direct bilirubin) in mg/dL from blood samples will be assessed for all participants.
Time frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
The change from baseline in alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP)
measurement of alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), all in U/L from blood samples will be assessed for all participants.
Time frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
Patients' symptoms, adverse events and toxicity
Adverse events and toxicity will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.
Time frame: 3 months.
Change in total antioxidant capacity (TAC) level
Assessment of total antioxidant capacity (TAC) level by ELISA Kits according to manufacturer's instructions.
Time frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
Change in tumor necrosis factor alpha (TNF-α)
Assessment of tumor necrosis factor alpha (TNF-α) level by ELISA Kits according to manufacturer's instructions
Time frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
Change in liver-fatty acid binding protein (L-FABP) level
Assessment of liver-fatty acid binding protein (L-FABP) level by ELISA Kits according to manufacturer's instructions.
Time frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine